NEW YORK--(BUSINESS WIRE)--Celmatix, a next-generation women’s health company, today announced the results of a new survey of 3,000 millennial women aimed at revealing their attitudes towards health and fertility. The market research survey, which included women between the ages of 22-35 who currently did not have children but were interested in having them one day, showed that millennial women are thinking about their fertility and are embracing both information and technology around it.
The survey revealed that 87 percent of women surveyed think about their ability to have children one day and that the majority of these women, 74 percent, are concerned about their ability to do so. With this concern comes a strong interest from millennial women to better understand their reproductive health. Nearly 75 percent of all respondents had discussed, or would like to discuss, their fertility with their OB-GYN. Nearly all women surveyed, 97 percent, were interested in learning how genetics might impact their health, with 80 percent of women specifically interested in the role that genetics may play in their fertility.
Findings also showed how open this generation of women is to using advanced medical technologies to conceive. Nearly 70 percent of women would consider using IVF if it would increase their chances of having the number of children they desired, with only 16 percent unsure and needing more information on the treatment option. Another 63 percent of women said they would consider egg freezing as an option to have children in the future, indicating a comfort among millennials in taking actions to better control their fertility timelines.
“Celmatix’s mission is to provide women and their physicians with better data, including genetic information, to help power more informed decisions on reproductive health,” explained Celmatix Chief Product Officer, Angie Lee. She continued, “The findings of this survey underscore the desire on the part of women, and particularly among millennial women, to leverage new technologies for greater insights into their reproductive health and more proactive management of their fertility potential.”
The digital survey included 3,000 college-educated women responding over a three-week period in December of 2016.
Women can learn more about the role of genetics in reproductive health by visiting www.myfertilome.com
About Celmatix
Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them with more personalized information. The company’s research-driven products include Fertilome®, the world’s first multigene panel test that reveals what a woman's DNA says about her reproductive health, and Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience. For more information, visit www.celmatix.com.
